Company Biography
A Tale of Two Schedules: A Study of the Efficacy and Toxicity Outcomes of Extended Durvalumab Dosing in Patients with Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC)
Link to Abstract. A PDF of the poster is available to download under the Resources tab
Contact Information
Name
Lilian Hanna
Email
hanna.lilian@gmail.com
You have chosen to your
information with
A Tale of Two Schedules: A Study of the Efficacy and Toxicity Outcomes of Extended Durvalumab Dosing in Patients with Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC)
Team Members
Wilma Hopman, MA
Queen's University
Research Methodologist
Andrea Fung, MD, PhD, FRCPC
Queen's University
Assistant Professor
Lilian Hanna, DO
Queen's University
Medical Oncology Fellow
Pierre-Olivier Gaudreau, MD, PhD, MPs, FRCPC
Canadian Cancer Trials Group / Queen's University
Senior Investigator